Role of Gene Polymorphism in Obesity and Cancer

Waseem, Mohammad; Husain, Hadiya; Ahmad, Imran

doi:10.1007/978-981-16-1846-8_7

Cited by 1 publication

(2 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that serum miRNA 711 was downregulated in both PCa and CRPC. Our previous study, Waseem et al (2017) [ 10 ], showed the downregulation of miRNA 711 in PCa tissue as compared to adjacent healthy tissue. Some studies have accounted for predicted and validated gene targets like GATA2, SKI, NTRK3, PAK2, AR, SP1, and CDK4 that describe their involvement in cancer progression [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…MiRNA 711 is reported to have significantly upregulated expression in head and neck cancer and urinary bladder cancer [ 9 ]. In our previous study, Waseem et al carried out microarrays among adjacent healthy tissue and PCa tissue to explore various differentially expressed miRNAs, including miRNA 183-5p, miRNA 4510, miRNA 711, and miRNA 329-3p [ 10 ]. In the current study, we are going to validate the expression of miRNA 183-5p, miRNA 4510, miRNA 711, and miRNA 329-3p in both tissue and serum of PCa and investigate their non-invasive biomarker potential as individual miRNAs as well as a panel of circulating miRNAs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery and Validation of Novel microRNA Panel for Non-Invasive Prediction of Prostate Cancer

Kumari,

Manoj,

Rungta

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Early diagnosis remains a challenge for prostate cancer (PCa) due to molecular heterogeneity. The purpose of our study was to explore the diagnostic potential of microRNA (miRNA) in both tissue and serum that may aid in the precise and early clinical diagnosis of PCa.Materials and methods: The miRNA expression pattern analysis was carried out in 250 subjects (discovery and validation cohort). The Discovery Cohort included the control (n = 30) and PCa (n = 35) subjects, while the Validation Cohort included the healthy control (n = 60), benign prostate hyperplasia (BPH) (n = 55), PCa (n = 50), and castration-resistant PCa (CRPC) (n = 20) patients. The expression analysis of tissue (Discovery Cohort) and serum (Validation Cohort) was carried out by quantitative polymerase chain reaction (qPCR). The diagnostic biomarker potential was evaluated using receiver operating characteristics (ROC). Bioinformatic tools were used to explore and analyze miRNA target genes.Results: MiRNA 4510 and miRNA 183 were significantly (p<0.001) upregulated and miRNA 329 was significantly (p<0.0001) downregulated in both PCa tissue and serum. ROC curve analysis showed excellent non-invasive biomarker potential of miRNA 4510 in both PCa (area under the curve (AUC) 0.984; p<0.001) and CRPC (AUC 0.944; p<0.001). The panel of serum miRNAs (miRNA 183 and miRNA 4510) designed for PCa had significant and greater AUC with both 100% sensitivity and specificity. Computational analysis shows that the maximum number of target genes are transcription factors that regulate oncogenes and tumor suppressors.Conclusion: Based on ROC curve analysis, miRNAs 4510, 329, and 711 were identified as potential noninvasive diagnostic biomarkers in the early detection of PCa. Our findings imply that a panel of miRNAs 183 and 4510 has high specificity for distinguishing PCa from healthy controls and providing therapeutic targets for better and earlier PCa therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%